☆ 4.8 Letter

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura

NEW ENGLAND JOURNAL OF MEDICINE (2016)

期刊

NEW ENGLAND JOURNAL OF MEDICINE

卷 374, 期 25, 页码 2497-2497

出版社

MASSACHUSETTS MEDICAL SOC

DOI: 10.1056/NEJMc1603180

关键词

-

类别

Medicine, General & Internal

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Hematology

Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura

George Goshua, Pranay Sinha, Jeanne E. Hendrickson, Christopher Tormey, Pavan K. Bendapudi, Alfred Ian Lee

Summary: The addition of caplacizumab to standard of care in acquired TTP treatment is not cost-effective due to the high cost of the medication and lack of improvement in relapse rates. Further study on the long-term impact of caplacizumab on health system cost is warranted.

BLOOD (2021)

添加到收藏夹

Article Hematology

A safe and effective use of caplacizumab in pregnancy-related acquired thrombotic thrombocytopenic purpura

Oluwatobi Odetola, Karlyn A. Martin, Marie Dreyer, Priya Rajan, Anaadriana Zakarija, Brady L. Stein

Summary: Managing TTP in pregnancy can be challenging, especially if traditional treatments are ineffective. Off-label use of caplacizumab may be a reasonable option in refractory cases to achieve disease control and prevent maternal and fetal morbidity and mortality.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

添加到收藏夹

Article Medicine, General & Internal

Post Approval Experience with Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura at a Single Institution

Constantine N. Logothetis, Ankita Patel, Jennifer Eatrides, Michael Jaglal, Mintallah Haider, Nathan Visweshwar, Damian A. Laber

Summary: This retrospective study found that using Caplacizumab in combination with glucocorticoids, rituximab, and therapeutic plasma exchange (TPE) for acquired thrombotic thrombocytopenic purpura (aTTP) is safe and effective, with 60% of patients achieving complete response.

JOURNAL OF CLINICAL MEDICINE (2021)

添加到收藏夹

Article Hematology

Brazilian experience with caplacizumab in acquired thrombotic thrombocytopenic purpura: outcomes of the expanded access program

Tiago de Oliveira Boechat, Joao Samuel de Holanda Farias, Eduardo Flavio Oliveira Ribeiro, Michaela Larissa Lobo de Andrade

Summary: In this study, the treatment effect of caplacizumab in 5 Brazilian patients with acquired thrombotic thrombocytopenic purpura was observed. All patients achieved clinical remission and had good control of the disease with minimal side effects.

ANNALS OF HEMATOLOGY (2023)

添加到收藏夹

Article Hematology

Mortality in acquired thrombotic thrombocytopenic purpura in the pre-caplacizumab era

Julio del Rio-Garma, Sabela Bobillo, Javier de la Rubia, Cristina Pascual, Faustino Garcia-Candel, Jose M. Garcia-Gala, Reyes Gonzalez, Laura Abril, Julia Vidan, Maria Jesus Gomez, Francisco Pena, Cristina Arbona, Jesus Martin-Sanchez, Gemma Moreno, Inigo Romon, Aurora Viejo, Ana Oliva, Monica Linares, Ramon Salinas, Sonia Perez, Jose A. Garcia-Erce, Arturo Pereira

Summary: The effectiveness of drug treatments plays a crucial role in the prognosis of patients with aTTP, with early symptoms and treatment response being key factors in predicting mortality risk.

ANNALS OF HEMATOLOGY (2022)

添加到收藏夹

Article Hematology

Immune thrombotic thrombocytopenic purpura in older patients: Results from the Spanish TTP Registry (REPTT)

I. Gomez-Segui, E. Frances Aracil, M. E. Mingot-Castellano, M. Vara Pampliega, R. Goterris Viciedo, F. Garcia Candel, C. Pascual Izquierdo, J. del Rio Garma, L. Guerra Dominguez, I. Vicuna Andres, J. Garcia-Arroba Peinado, S. Zalba Marcos, J. M. Vidan Estevez, E. Gonzalez Arias, V. Campuzano Saavedra, J. M. Garcia Gala, S. Ortega Sanchez, J. Martinez Nieto, L. Pardo Gambarte, M. Sole Rodriguez, M. Fernandez-Docampo, L. F. Avila Idrovo, L. Hernandez, J. Cid, J. de la Rubia Comos

Summary: The clinical characteristics and treatment response of immune thrombotic thrombocytopenic purpura (iTTP) in older patients were analyzed and compared with younger patients. Similar symptoms and laboratory results were observed in both groups, but older patients had a higher incidence of renal dysfunction. The frontline treatment and clinical outcomes did not differ between the two age groups. Notably, the use of caplacizumab and rituximab showed favorable safety and efficacy profiles in older patients.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

添加到收藏夹

Review Hematology

The standard of care for immune thrombotic thrombocytopenic purpura today

X. Long Zheng

Summary: For immune thrombotic thrombocytopenic purpura (iTTP), the triple therapy consisting of therapeutic plasma exchange, caplacizumab, and immunosuppressives has been proven to be an effective treatment for acute episodes, accelerating platelet count normalization, reducing ICU and hospital stays, and most importantly, lowering mortality rate.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)

添加到收藏夹

Article Cell Biology

Successful use of a second course of caplacizumab in relapsed thrombotic thrombocytopenic purpura

Jon Shaffer, Angela Grove

Summary: This case report demonstrates the efficacy of a second course of caplacizumab in a patient with relapsed TTP, showing significant improvement in platelet count. The patient was able to complete the treatment successfully without complications or further relapses.

PLATELETS (2022)

添加到收藏夹

Review Medicine, General & Internal

Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management

Senthil Sukumar, Bernhard Lammle, Spero R. Cataland

Summary: TTP is a rare but dangerous disorder characterized by hemolysis, thrombocytopenia, and ischemic damage, often caused by ADAMTS13 deficiency. Front-line treatment typically involves plasma exchange and immunosuppression, as well as drugs like rituximab and caplacizumab. Refractory cases may require alternative therapies.

JOURNAL OF CLINICAL MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Caplacizumab for immune thrombotic thrombocytopenic purpura: real-world multicenter data

Eleni Gavriilaki, Emmanuel Nikolousis, Eudoxia-Evaggelia Koravou, Sotiria Dimou-Besikli, Charalampos Kartsios, Anna Papakonstantinou, Anastasia Mpanti, Charalampos Pontikoglou, Christina Kalpadaki, Aikaterini Bitsani, Ilianna Tassi, Tasoula Touloumenidou, Thomas Chatziconstantinou, Maria Papathanasiou, Antonia Syrigou, Eleutheria Ztriva, Georgia Kaiafa, Evdokia Mandala, Zois Mellios, Dimitrios Karakasis, Alexandra Kourakli, Argiris Symeonidis, Eleni Kapsali, Helen H. Papadaki, Chrysavgi Lalayanni, Ioanna Sakellari

Summary: A multicenter real-world study was conducted to assess the safety and efficacy of caplacizumab in treating immune thrombotic thrombocytopenic pupura (iTTP). The results showed that caplacizumab is safe and effective in treating iTTP, including cases refractory to plasma exchange. Discontinuation of dosing guided by ADAMTS13 activity can lower the relapse rate.

FRONTIERS IN MEDICINE (2023)

添加到收藏夹

Article Hematology

Effectiveness of Caplacizumab Nanobody in Acquired Thrombotic Thrombocytopenic Purpura Refractory to Conventional Treatment

Tomas Palanques-Pastor, Juan Eduardo Megias-Vericat, Virginia Boso Ribelles, Ines Gomez Segui, Jose Luis Poveda Andres

Summary: Acquired thrombocytopenic thrombotic purpura (aTTP) is an autoantibody-mediated disease traditionally treated with plasma exchange and corticosteroids, but the newer therapy caplacizumab has shown better disease control, especially in cases of recurrent relapses.

ACTA HAEMATOLOGICA (2022)

添加到收藏夹

Article Hematology

Should all patients with immune-mediated thrombotic thrombocytopenic purpura receive caplacizumab?

Adrien Picod, Agnes Veyradier, Paul Coppo

Summary: iTTP is a rare and life-threatening disease currently treated with TPE and immunosuppression, while caplacizumab, a new treatment, shows faster platelet count recovery, decreased adverse outcomes, and reduced burden of care by inhibiting platelet aggregation and microthrombi formation.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)

添加到收藏夹

Article Urology & Nephrology

Immune-mediated thrombotic thrombocytopenic purpura in childhood treated by caplacizumab, about 3 cases

Julie Boudali, Benjamin Hallak, Marie Haeck, Anne-Laure Sellier-Leclerc, Marc Ulrich, Paul Coppo, Stephanie Tellier, Francois Provot

Summary: Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is rare in children, but three children were successfully treated with caplacizumab.

JOURNAL OF NEPHROLOGY (2022)

添加到收藏夹

Editorial Material Hematology

Caplacizumab: A game changer also in pregnancy-associated immune-mediated thrombotic thrombocytopenic purpura?

Paul Coppo, Berangere S. Joly

Summary: Therapeutic options for iTTP during pregnancy are limited, but caplacizumab may be a reasonable option when standard therapies are not effective, according to Odetola et al.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

添加到收藏夹

Article Hematology

Von Willebrand factor assays in patients with acquired immune thrombotic thrombocytopenia purpura treated with caplacizumab

Annette Bowyer, Paula Brown, Barbara Hopkins, Marie Scully, Fiona Shepherd, Anna Lowe, Patrick Mensah, Rhona Maclean, Steve Kitchen, Joost J. van Veen

Summary: Acquired immune thrombotic thrombocytopenic purpura (iTTP) is a rare disease caused by autoantibodies to the von Willebrand factor (VWF) cleaving protease. Caplacizumab, an immunoglobulin targeting VWF, has shown to effectively treat iTTP. This study investigated the VWF parameters of 11 iTTP patients treated with Caplacizumab and found that VWF antigen and collagen binding activity levels were normal or borderline normal, while VWF activity assays varied depending on reagents and patients.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

添加到收藏夹

Letter Hematology

Reduced FVIII recovery associated with anti-FVIII PEG antibodies after BNT162b2 SARS-CoV-2 vaccination

Carla Valsecchi, Roberta Gualtierotti, Sara Arcudi, Alessandro Ciavarella, Lucia Schiavone, Cristina Novembrino, Simona Maria Siboni, Pier Mannuccio Mannucci, Flora Peyvandi

BLOOD ADVANCES (2023)

添加到收藏夹

Article Hematology

Recombinant factor VIII Fc fusion protein for first-time immune tolerance induction: final results of the verITI-8 study

Lynn Malec, An Van Damme, Anthony K. C. Chan, Mariya Spasova, Nisha Jain, Charlotte Sensinger, Jennifer Dumont, Stefan Lethagen, Manuel Carcao, Flora Peyvandi

Summary: Inhibitor development remains a major challenge in factor VIII replacement therapy. The verITI-8 study evaluated the use of a recombinant FVIII Fc fusion protein (rFVIIIFc) for immune tolerance induction in males with severe hemophilia A and high-titer inhibitors. The study showed that rFVIIIFc achieved tolerization in a significant number of patients within a short time period, and adverse events were generally well tolerated.

BLOOD (2023)

添加到收藏夹

Editorial Material Gastroenterology & Hepatology

Liver-related aspects of gene therapy for haemophilia: Call to action for collaboration between haematologists and hepatologists

Wolfgang Miesbach, Graham R. Foster, Flora Peyvandi

JOURNAL OF HEPATOLOGY (2023)

添加到收藏夹

Review Hematology

Prevalence of selected bleeding and thrombotic events in persons with hemophilia versus the general population: A scoping review

Amy D. Shapiro, Brandon M. Hardesty, Flora Peyvandi, Alfonso Iorio

Summary: Life expectancy for persons with hemophilia has increased due to advances in treatment, but they are now more likely to be affected by conditions associated with aging. This study analyzed the prevalence of bleeding and thrombotic events in hemophilia populations compared to the general population. The results showed consistently higher rates of bleeding events in hemophilia populations, while the prevalence of arterial thrombosis varied.

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2023)

添加到收藏夹

Review Hematology

International Council for Standardization in Haematology recommendations for laboratory measurement of factor VIII and FIX type I inhibitors

Piet Meijer, Flora Peyvandi, Guy Young, Rajiv Pruthi, Silmara de Lima Montalvao, Steve Kitchen

Summary: This guidance document provides recommendations on the measurement of factor VIII (FVIII) and factor IX (FIX) inhibitors, including screening, assay principle, sample and testing requirements, interpretation, quality assurance, interferences, and recent developments. It focuses on standardizing the laboratory measurement of FVIII and FIX type I inhibitors based on published data and expert opinion.

INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2023)

添加到收藏夹

Article Medicine, General & Internal

Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A

J. Mahlangu, R. Kaczmarek, A. von Drygalski, S. Shapiro, S. -C. Chou, M. C. Ozelo, G. Kenet, F. Peyvandi, M. Wang, B. Madan, N. S. Key, M. Laffan, A. L. Dunn, J. Mason, D. V. Quon, E. Symington, A. D. Leavitt, J. Oldenburg, H. Chambost, M. T. Reding, K. Jayaram, H. Yu, R. Mahajan, K. -M. Chavele, D. B. Reddy, J. Henshaw, T. M. Robinson, W. Y. Wong, S. W. Pipe

Summary: This study demonstrates the long-term effectiveness and safety of valoctocogene roxaparvovec therapy in reducing bleeding events in men with severe hemophilia A. The pharmacokinetic modeling suggests a half-life of 123 weeks for the transgene-derived factor VIII production system. Models also indicate a similar relationship between factor VIII activity and bleeding episodes as observed in individuals with mild-to-moderate hemophilia A using epidemiologic data.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

添加到收藏夹

Editorial Material Medicine, General & Internal

Mild and Moderate Hemophilia A: Neglected Conditions, Still with Unmet Needs

Giancarlo Castaman, Flora Peyvandi, Raimondo De Cristofaro, Berardino Pollio, Dario M. N. Di Minno

JOURNAL OF CLINICAL MEDICINE (2023)

添加到收藏夹

Article Medicine, General & Internal

Nailfold Videocapillaroscopic Alterations as Markers of Microangiopathy in COVID-19 Patients

Roberta E. Gualtierotti, Sharon Fox, Fernanda Da Silva Lameira, Andrea Giachi, Luca Valenti, Maria Orietta Borghi, Pier Luigi Meroni, Massimo Cugno, Flora Peyvandi

Summary: Nailfold videocapillaroscopic alterations were observed in COVID-19 patients, and these alterations were correlated with biomarkers of inflammation and endothelial perturbation. Nailfold histopathology analysis revealed microvascular damage and microthrombi in some cases. These findings suggest the possibility of non-invasively demonstrating microangiopathy in COVID-19.

JOURNAL OF CLINICAL MEDICINE (2023)

添加到收藏夹

Review Biochemistry & Molecular Biology

Laboratory Diagnosis of Antiphospholipid Syndrome in Anticoagulated Patients

Armando Tripodi, Erica Scalambrino, Marigrazia Clerici, Flora Peyvandi

Summary: The laboratory diagnosis of APS requires the measurement of solid-phase antibodies to cardiolipin or β2-Glycoprotein-I and the search for LA. However, the interpretation of results, especially for LA, is difficult in patients on anticoagulation due to the overlap of clotting time prolongations induced by LA and anticoagulants. This article reviews the effect of anticoagulants on APS diagnosis and discusses potential solutions to overcome this issue.

BIOMEDICINES (2023)

添加到收藏夹

Article Hematology

A comparative study in patients with type 2 von Willebrand disease using 4 different platelet-dependent von Willebrand factor assays

Paola Colpani, Luciano Baronciani, Francesca Stufano, Giovanna Cozzi, Marco Boscarino, Maria Teresa Pagliari, Eugenia Biguzzi, Flora Peyvandi

Summary: This study evaluated four different assays to diagnose and detect various von Willebrand disease (VWD) variants. The VWF:GPIbM-automated assay was the most effective in diagnosing type 2B, while the VWF:RCo assays were the most effective in detecting type 2M and 2M/2A variants. The VWF:GPIbM ELISA overestimated the activity of type 2B patients lacking high-molecular-weight multimers (HMWM). Using a VWF activity/VWF:antigen ratio cut-off of 0.70 reduced the number of misdiagnosed patients by half.

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2023)

添加到收藏夹

Article Hematology

Accreditation model of European Haemophilia Centres in the era of novel treatments and gene therapy

Ana Boban, Fariba Baghaei, Fijnvandraat Karin, Robert Klamroth, Wolfgang Miesbach, David Stephensen, Mary Kavanagh, Declan Noone, Miguel Crato, Flora Peyvandi

Summary: This article introduces the background and purpose of international certification of haemophilia centres in Europe, as well as the methods and results of establishing a new accreditation protocol.

HAEMOPHILIA (2023)

添加到收藏夹

Article Medicine, General & Internal

Characterization of Immunogenicity and Safety of COVID-19 mRNA-1273 in HIV-Positive Italian Patients with Hemophilia: A Prospective Single-Center Cohort Study

Chiara Suffritti, Roberta Gualtierotti, Sara Arcudi, Alessandro Ciavarella, Cristina Novembrino, Anna Lecchi, Silvia La Marca, Lidia Padovan, Erica Scalambrino, Marigrazia Clerici, Patrizia Bono, Ferruccio Ceriotti, Antonio Muscatello, Simona Maria Siboni, Flora Peyvandi

Summary: This study investigated the immunogenicity of the mRNA-1273 vaccine in HIV-positive hemophilic patients during the third COVID-19 wave in Italy and examined biomarkers of coagulation and endothelial perturbation after complete vaccination. The results showed that all patients had effective immunization with anti-spike antibodies two weeks after completing the vaccination schedule. Furthermore, the vaccination had no significant effects on coagulation and endothelial perturbation.

JOURNAL OF CLINICAL MEDICINE (2023)

添加到收藏夹

Article Genetics & Heredity

Population-based prevalence and mutational landscape of von Willebrand disease using large-scale genetic databases

Omid Seidizadeh, Andrea Cairo, Luciano Baronciani, Luca Valenti, Flora Peyvandi

Summary: In this study, the global prevalence of Von Willebrand disease (VWD) was estimated by analyzing exome and genome data from a large number of individuals. The results showed a higher than expected prevalence of potential disease alleles and variants associated with VWD.

NPJ GENOMIC MEDICINE (2023)

添加到收藏夹

Article Hematology

Minimum factor VIII levels to prevent joint bleeding in mild hemophilia A

Pasquale Agosti, Simona Maria Siboni, Sara Scardo, Adriana Torri, Roberta Gualtierotti, Flora Peyvandi

Summary: This study aimed to identify the minimum FVIII levels necessary to prevent joint bleeds in patients with hemophilia A. The findings suggest important implications for the design of prophylactic therapies for moderate and severe hemophilia A.

BLOOD ADVANCES (2023)

添加到收藏夹

Letter Hematology

Comment on: A comparative study in type 2 von Willebrand disease patients using four different platelet-dependent von Willebrand factor assays

Paola Colpani, Luciano Baronciani, Giovanna Cozzi, Maria Teresa Pagliari, Eugenia Biguzzi, Flora Peyvandi

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2023)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.